Viridian may have edge over Amgen in eye drug showdown, analysts argue
Source ↗
👁 0
💬 0
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
Comments (0)